Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Nephrotoxicity associated with ifosfamide

  • 63 Accesses

  • 58 Citations


Three patients developed a Fanconi syndrome with impairment of glomerular function (endogenous creatinine clearance 30–60 ml/min per 1.73 m2) during and/or after treatment with ifosfamide according to the SIOP-MMT 84 protocol in which ifosfamide was given in a dose of 3000 mg/m2 every 4 weeks over a 10-month period. The need for early substitution therapy in patients with the Fanconi syndrome is stressed. The renal lesions in our patients were irreversible.

This is a preview of subscription content, log in to check access.


MMT 84:

malignant mesenchymal tumours 1984


ifosfamide, vincristine, actinomycin D


  1. 1.

    Brodehl J (1978) The Fanconi syndrome. In: Edelmann CM Jr (ed) Pediatric kidney disease. Little Brown, Boston, pp 955–987

  2. 2.

    Brunat-Mentigny M, Dutou L, Flamant F, Olive D, Otten J, Quintana E, Rodary C, Voute PA, Cailland JM, Marsden M, Unnik A van (1984) Protocol for the treatment of malignant mesenchymal tumours in children. SIOP (Societé Internationale d'Oncologie Pediatrique)

  3. 3.

    Ghazali S, Barratt T (1974) Urinary excretion of calcium and magnesium in children. Arch Dis Child 49:97–101

  4. 4.

    Heim ME, Fiene R, Schick E, Wolpert E, Queiber W (1981) Central nervous system side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100:113–116

  5. 5.

    Hilgard P, Burkert H (1984) Sodium-2-mercapto-ethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 20:1451–1452

  6. 6.

    Ingelfinger JR (1987) Persistent renal-genitourinary disorders. Nijhoff, Boston, pp 95–109

  7. 7.

    Kehl A, Bergholz M, Heyden HW von, Nagel G-A (1983) Toxisch allergisches Lungenödem nach Cyclophosphamid-und Ifosfamid Therapie. Onkologie 6:84–86

  8. 8.

    Kreusser W, Herrmann R, Tschöpe W, Ritz E (1982) Nephrological complications of cancer therapy. Contrib Nephrol 33:223–238

  9. 9.

    Kruse K, Kracht U, Göpfert G (1982) Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 57:217–223

  10. 10.

    Monnens L, Smulders Y, Lier H van, Boo T de (1981) DDAVP test for assessment of renal concentrating capacity in infants and children. Nephron 29:151–154

  11. 11.

    Ries F, Klasterysky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis to cisplatin toxicity. Am J Kidney Dis 8:368–379

  12. 12.

    Sangster G, Kaye SB, Calman KC, Dalton JF (1984) Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Oncol 20:435–436

  13. 13.

    Schärer K (1980) Nephrotoxic action of immunosuppressive and cytostatic agents. Helv Paediatr Acta 41:103–104

Download references

Author information

Correspondence to J. Smeitink.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Smeitink, J., Verreussel, M., Schröder, C. et al. Nephrotoxicity associated with ifosfamide. Eur J Pediatr 148, 164–166 (1988). https://doi.org/10.1007/BF00445929

Download citation

Key words

  • Ifosfamide
  • Fanconi syndrome
  • Disturbances of glomerular filtration